SecBot SecBot
SECBOTREPLAY Home › Report › ANVS

ANVS · Annovis Bio announced full enrollment of its pivotal Phase 3 trial…

Annovis Bio, Inc. · 8-K filed Jul 9, 2026 at 21:06 ET

At the news

NEUTRALIMPACT 6/10

8-K filed Jul 9, 2026 at 21:06 ET

Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for early Alzheimer's disease, enrolling 850 patients across 83 US sites, exceeding original projections. The dual-readout trial provides symptomatic data in Q1 2027 and disease-modifying data in Q1 2028, with NDA submissions targeted after each readout. This is an operational milestone that de-risks trial execution but provides no efficacy data, leaving the binary outcome intact.

  • Full enrollment of 850 patients in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease, exceeding original projections
  • Trial conducted across 83 clinical sites in the US with pTau217-confirmed AD pathology
  • 6-month symptomatic top-line data readout expected Q1 2027
  • 18-month disease-modifying top-line data readout expected Q1 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access